IMU 9.26% 5.9¢ imugene limited

Media Thread, page-5843

  1. 1,070 Posts.
    lightbulb Created with Sketch. 451
    Amazing results. And similarish kind of method to cf33,
    https://www.cgoncology.com/pipeline/

    "Cancer-selective oncolytic immunotherapy designed for tolerability and potency

    CG0070 is an investigational oncolytic immunotherapy based on a modified common cold adenovirus backbone that contains a cancer-specific promoter and a GM-CSF transgene. CG0070 was designed to work in two important and complementary ways. First, it replicates inside the tumor’s cells causing tumor cell lysis and immunogenic cell death. Then, the rupture of the cancer cells can release tumor-derived antigens, along with GM-CSF, that can stimulate a systemic anti-tumor immune response that involves the body’s own white blood cells. The scientific rationale and clinical profile of CG0070 make it an ideal agent to be developed for a variety of solid tumor types to be used alone or in combination with immune checkpoint modulators."

 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.